An observational study in Breast Cancer Females, sponsored by University of Toronto. Recruiting at 1 site in Canada. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by University of Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Obesity by University of Toronto — 4 open to participants now, 7 under way, none of them phase 3. Obesity · University of Toronto.
Among the 53 studies in Obesity by University of Toronto, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2025, is one of 12 observational ones, and was the 52nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →4 of the 53 studies in Obesity by University of Toronto are open now, in 1 country. Recruiting first, the newest first:
University of Toronto · Sites in Canada
Ages 14–80
University of Toronto · Sites in Canada
Ages 40+
University of Toronto · Sites in Canada
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3
First in 2002; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 40 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 30 across the 38 interventional studies, 1 across the 12 observational. Of the 35 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.
3 of the studies in Obesity by University of Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781762University of TorontoShort-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer | 2026-12-30 |
| NCT06879652University of TorontoThe Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors | 2027-06 |
| NCT06118931University of TorontoTime-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control | 2027-06-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Obesity by University of Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of cardiovascular events and mortality, the underlying mechanisms contributing to this risk remain unknown. This study will characterize the short-term effects of aromatase inhibitor therapy on established and novel health indices for cardiovascular diseases in breast cancer patients.
Using a longitudinal case-control design this study will assess the effects of short-term (first 6 months) aromatase inhibitor use in breast cancer patients compared to age- and BMI-matched controls, aiming to determine the cardiovascular, metabolic, and behavioural health impacts of endocrine treatment during this early period. Specifically, our objectives are as follows:
The investigators hypothesize that cardiovascular and metabolic health outcomes will be similar between breast cancer survivors and controls at baseline but will deteriorate relative to controls within the first 6 months of aromatase inhibitor therapy.
Case participants will be recruited from Princess Margaret Cancer Centre in Toronto. Control participants will be local participants in the greater Toronto area, recruited through posters, newsletters, social media advertisements, and word of mouth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Case group:
Control group:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Breast Cancer patients using aromatase inhibitors for 6 months
Other: N/A (Usual Care)
Arm Description: A woman without a history of cancer will be recruited to match each patient with breast cancer on age and BMI (within 3 years and 3 kg/m2, whenever possible)
BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
Aortic Stiffness
Aortic stiffness, measured non-invasively by pulse wave velocity, will be assessed using applanation tonometry. Measurements will be taken at rest and every 30min during a 2h oral glucose tolerance test.
Time frame: Baseline, 6 months
Brachial Artery Endothelial Function
Endothelial function will be assessed using the gold standard method of flow mediated dilation (FMD) using non-invasive duplex ultrasound (GE Vivid IQ) and edge-tracking software. Measurements will be taken at rest and every 30min during a 2h oral glucose tolerance test.
Time frame: Baseline, 6 months
Carotid Artery Stiffness
Functional assessment of the carotid artery stiffness will be assessed using B-mode ultrasound and artery edge-tracking software
Time frame: Baseline, 6 months
Carotid Intima Media Thickness
Structural assessment of the carotid artery thickness will be assessed using B-mode ultrasound and artery edge-tracking software
Time frame: Baseline, 6 months
Left Ventricular Ejection Fraction (LVEF)
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, represented as a % using the following formula: stroke volume/end diastolic volume x 100%.
Time frame: Baseline, 6 months
Global Longitudinal Strain
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, expressed as a percentage of the relative change in length of the left ventricle through a cardiac cycle.
Time frame: Baseline, 6 months
Left Ventricular Diastolic Function
Cardiac outcomes will be assessed via echocardiography (GE Vivid IQ) and analyzed using Echopac software, assessed by the ratio of peak early diastolic velocity to peak mitral valve velocity (E/A ratio).
Time frame: Baseline, 6 months
Arterial Stiffness
Measured by Pulse Wave Velocity (PWV) of the arm and leg
Time frame: Baseline, 6 months
Cerebrovascular Response
Cerebral blood flow velocity response (delta change compared to rest) of the middle cerebral artery will be assessed using transcranial Doppler ultrasound (Neurovision Transcranial Doppler System Model 500M) in accordance with recent guidelines, in response to postural changes (sit-to-stand) and exercise (squatting).
Time frame: Baseline, 6 months
Brain Derived Neurotrophic Factor
Brain derived neurotrophic factor will be assessed via fasted venipuncture using in-house assays.
Time frame: Baseline, 6 months
Lipid profile
HDL, LDL, total Cholesterol, Triglycerides analyzed from blood serum using a clinical assay at a core lab.
Time frame: Baseline, 6 months
Hemoglobin A1c
Analyzed from blood plasma using a clinical assay at a core lab.
Time frame: Baseline, 6 months
Insulin resistance
Calculated as Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from fasting blood measures of glucose and insulin, analyzed using a clinical assay at a core lab. Matsuda Index will also be calculated using a standard equation requiring fasting insulin and glucose and area under the curve of the post-ingestion of 75g of glucose insulin and glucose concentrations measured at 30, 60, 90 and 120 minutes.
Time frame: Baseline, 6 months
Cardiorespiratory fitness
Measured as peak volume of oxygen consumption via indirect calorimetry during a cardiopulmonary exercise test on a cycle ergometer.
Time frame: Baseline, 6 months
Framingham 10-year cardiovascular risk (%)
Calculated using the standardized scoring system where sex-specific points are assigned to age, systolic blood pressure (dependent on treatment status), HDL, total cholesterol, smoking and diabetes status. The range for females is 0-30% where a higher score indicates a greater risk of cardiovascular disease in the next 10 years.
Time frame: Baseline, 6 months
Heart Rate Recovery
Measured as the difference between peak heart rate during the cardiorespiratory fitness test and heart rate 2-minutes into active recovery after stopping the exercise test.
Time frame: Baseline, 6 months
Heart Rate Variability
Measured as the variability in beat-to-beat heart rate during supine rest.
Time frame: Baseline, 6 months
avO2 difference
Measured by a non-invasive optical technique used to assess tissue oxygenation and hemodynamics (Near-Infrared Spectroscopy - NIRS) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Baseline, 6 months
Cardiac Output
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Baseline, 6 months
Stroke Volume
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Baseline, 6 months
Resting Blood Pressure
Measured as the average of the last 5 of 6 blood pressure measurements taken 60 seconds apart using an automatic blood pressure device.
Time frame: Baseline, 6 months
Beat-by-beat Blood Pressure
Measured continuously by a finger cuff (Finger Arterial Pressure - Finapres) at rest, and during cycling exercise at ventilatory threshold, respiratory compensation point, and peak oxygen uptake.
Time frame: Baseline, 6 months
Glucose Levels
Measured during a 10-day period by a Dexcom G7 Continuous Glucose Monitor (CGM)
Time frame: Baseline, 6 months
Hemoglobin
Analyzed from blood plasma using a clinical assay at a core lab.
Time frame: 6 months
Whole-body fat mass
Measured using a body composition device (BodPod) to estimate whole body fat (in kg and %).
Time frame: Baseline, 6 months
Whole-body fat-free mass
Measured using a body composition device (BodPod) to estimate whole body fat free mass (in kg and %).
Time frame: Baseline, 6 months
Waist Circumference
Circumference of the waist measured using an inelastic tape
Time frame: Baseline, 6 months
Hip Circumference
Circumference of the hip measured using an inelastic tape
Time frame: Baseline, 6 months
Neck Circumference
Circumference of the neck measured using an inelastic tape
Time frame: Baseline, 6 months
Body weight
Assessed fasted in lab using a calibrated scale
Time frame: Baseline, 6 months
Body mass index (BMI)
Calculated from a measurement of height using a stadiometer and body weight (detailed above).
Time frame: Baseline, 6 months
Dietary intake
Various components of dietary intake including macronutrients and micronutrients will be assessed through 3-day food records over 2 weekdays and 1 weekend collected using ASA-24 online system.
Time frame: Baseline, 6 months
Diet quality
An overall measure of alignment with Canada's dietary guidelines measured via the Healthy Eating Food Index-2019 calculated from 3-day diet records
Time frame: Baseline, 6 months
Depression & Anxiety
Measured by the Hospital Anxiety and Depression Scale (HADS); score ranges from 0-21 for each of depression and anxiety with a higher score indicating more severe depression or anxiety
Time frame: Baseline, 6 months
Autonomic symptoms
Assessed by the COMPASS 31 (Composite Autonomic Symptom Score) questionnaire. This questionnaire provides clinically relevant scores of autonomic symptom severity. Scores range from 0 to 31 with questions in six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor, with a higher scoring indicating worse autonomic dysfunction.
Time frame: Baseline, 6 months
Cognitive Function: Verbal Fluency
Assessed using the Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency), with higher number of words produced indicative of better cognitive health.
Time frame: Baseline, 6 months
Cognitive Function: Verbal Learning & Memory
Assessed the Hopkins Verbal Learning Test (learning, memory) with an immediate recall, delayed recall, and recognition accuracy from a list of 12 words. Higher number of words are indicative of better cognitive health.
Time frame: Baseline, 6 months
Cognitive Function: Processing Speed
Assessed by the Trail Making Test (attention, speed, executive function). Shorter test time on 2 forms of the test is indicative of better cognitive health.
Time frame: Baseline, 6 months
Cognitive Impairment (Composite Measure)
Assessed by Global Deficit Score (GDS). GDS is calculated as an average score from 3 tests previously described in outcomes 36, 37, and 38: 1) Hopkins Verbal Learning Test (learning, memory), 2) Trail Making Test (attention, speed, executive function), 3) Controlled Oral Word Association of the Multilingual Aphasia Exam (verbal fluency). Each subtest of the GDS has a complex scoring system, detailed above, with higher values indicating greater cognitive deficits.
Time frame: Baseline, 6 months
Cancer-specific Quality of life (only assessed in cancer group): General
Assessed using the Functional Assessment of Cancer Therapy - General (FACT-G). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-G is calculated from the sum of four subscales on general health related quality of life with a range of 0-108 points. Higher scores on each scale is indicative of better quality of life.
Time frame: Baseline, 6 months
Cancer-specific Quality of life (only assessed in cancer group): Endocrine
Assessed using the Functional Assessment of Cancer Therapy - Endocrine (FACT-ES). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-ES is a score of 19 questions with scores ranging from 0-76. Higher scores on each scale is indicative of better quality of life.
Time frame: Baseline, 6 months
Cancer-specific Quality of life (only assessed in cancer group): Cognitive
Assessed using the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. The FACT-Cog contains 37 questions with a score of 0 to 132. Higher scores on each scale is indicative of better quality of life.
Time frame: Baseline, 6 months
Cancer-specific Quality of life (only assessed in cancer group): Fatigue
Assessed using the Functional Assessment of Cancer Therapy - Fatigue (FACT-F). This is a patient-reported outcome measurement used to assess health-related quality of life in patients with a history of cancer. FACT-F is calculated from the sum of 13 questions. Higher scores on each scale is indicative of better quality of life.
Time frame: Baseline, 6 months
Musculoskeletal health
Assessed using the Musculoskeletal Health Questionnaire (MSK-HQ). The MSK-HQ is a series of 15 questions with a range from 0-56 with higher scores being indicative of poorer MSK health.
Time frame: Baseline, 6 months
Musculoskeletal pain
Assessed using the Brief Pain Inventory (BPI). The BPI is scored as the average of seven pain-related questions with a range of 0-10 with higher scores representing greater pain.
Time frame: Baseline, 6 months
Musculoskeletal osteoarthritis risk
Assessed using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. The WOMAC is a series of 17 questions resulting in a % (0-100) with higher scores indicative of greater osteoarthritis index.
Time frame: Baseline, 6 months
Musculoskeletal disability
Assessed using the Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire. The DASH contains 30 questions with scores of 0 to 100 with higher scores representing higher severity in disability.
Time frame: Baseline, 6 months
Cardiovascular risk
Assessed using the INTERHEART Risk Score, a validated score for quantifying risk-factor burden without the use of laboratory testing (with higher scores indicating greater risk-factor burden).
Time frame: Baseline, 6 months
Gender-Related Factors
Assessed by the Stanford Gender-related Variables for Health Research (GVHR) which includes questions related to seven gender-related variables: caregiver strain, work strain, independence, risk-taking, emotional intelligence, social support, and discrimination.
Time frame: Baseline
Health-related quality of life
Assessed by RAND-36, where an independent score is provided for 8 scales ranging from 0 to 100 and 2 component summary scales ranging from 0-50 with a higher score indicating better quality of life.
Time frame: Baseline, 6 months
Psychosocial stress
Assessed by the perceived stress scale (PSS-14) where individual scores can range from 0 to 56 with higher scores indicating higher perceived stress
Time frame: Baseline, 6 months
Sleep quality - subjective
Subjectively assessed by the Pittsburgh Sleep Quality Index (PQSI), which measures components of sleep: sleep duration, disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use, with higher scores reflecting poorer sleep quality. From these 7 questions, a global score of 0 to 21 is created with higher values indicative of poorer sleep quality.
Time frame: Baseline, 6 months
Sleep quantity - device measured
Measured via Garmin smartwatch for the total sleep duration.
Time frame: Baseline, 6 months
Sleep quality - device measured
Measured via Garmin smartwatch for the total sleep efficiency.
Time frame: Baseline, 6 months
Moderate-Vigorous Physical Activity
Measured via Garmin smartwatch for time in moderate-vigorous physical activity in total minutes at this intensity.
Time frame: Baseline, 6 months
Physical activity: step counts
Measured via Garmin smartwatch for daily step counts.
Time frame: Baseline, 6 months
Sedentary time
Measured via Garmin smartwatch for time spent sitting.
Time frame: Baseline, 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 18 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.